Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Cash (2016 - 2025)

ImmunityBio (IBRX) has disclosed Change in Cash for 12 consecutive years, with $28.1 million as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 11.13% to $28.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$54.5 million through Dec 2025, up 55.3% year-over-year, with the annual reading at -$54.5 million for FY2025, 55.3% up from the prior year.
  • Change in Cash for Q4 2025 was $28.1 million at ImmunityBio, up from -$76.8 million in the prior quarter.
  • The five-year high for Change in Cash was $134.5 million in Q3 2023, with the low at -$144.7 million in Q1 2022.
  • Average Change in Cash over 5 years is $2.7 million, with a median of $5.1 million recorded in 2021.
  • The sharpest move saw Change in Cash tumbled 1582.14% in 2022, then skyrocketed 18127.08% in 2023.
  • Over 5 years, Change in Cash stood at $116.6 million in 2021, then crashed by 99.59% to $480000.0 in 2022, then surged by 18127.08% to $87.5 million in 2023, then tumbled by 63.87% to $31.6 million in 2024, then dropped by 11.13% to $28.1 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $28.1 million, -$76.8 million, and $77.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.